Malaria is the leading parasitic infectious disease in the tropics. The heaviest burden is borne by children in Africa, where more than 2 million succumb to this dreaded disease every year. The critical pathway for vaccine development requires the conduct of safety (Phase 1A) vaccine trials in the United States, followed by safety and efficacy (Phase1B/ 2B) vaccine trials at sites where malaria transmission is endemic. Two projects are organized around the central theme of developing a safe and effective malaria vaccine to prevent disease and death due to falciparum malaria in African children. Interventional clinical trials of a malaria vaccine candidate will be conducted in Project 1, and samples from Project 1 will be analyzed in Project 2 to address important questions that will inform the vaccine development and testing process. Administrative and biostatistical cores will support both projects. Our other main objective is to provide research experience for U.S. and Malian scientists and to strengthen the already strong linkages between U.S. and Malian investigators to enhance the independent research capacity of the University of Bamako, Mali. The majority of the proposed research will be conducted in Mali, at the Bandiagara Malaria Project clinical trials site and at the Malaria Research and Training Center at the University of Bamako. The U.S. and Malian investigators will collaborate closely in the design, implementation, monitoring, and management of the research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-GSM-M (M1))
Program Officer
Rosenthal, Steven R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Graves, Shawna F; Kouriba, Bourema; Diarra, Issa et al. (2016) Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine 34:2546-55
Malaria Genomic Epidemiology Network; Band, Gavin; Rockett, Kirk A et al. (2015) A novel locus of resistance to severe malaria in a region of ancient balancing selection. Nature 526:253-7
Travassos, Mark A; Coulibaly, Drissa; Bailey, Jason A et al. (2015) Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. Am J Trop Med Hyg 92:1190-4
Gandhi, Kavita; Thera, Mahamadou A; Coulibaly, Drissa et al. (2014) Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. PLoS One 9:e101783
Ouattara, Amed; Takala-Harrison, Shannon; Thera, Mahamadou A et al. (2013) Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207:511-9
Travassos, Mark A; Niangaly, Amadou; Bailey, Jason A et al. (2013) Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults. J Infect Dis 208:1514-9
Thera, Mahamadou A; Plowe, Christopher V (2012) Vaccines for malaria: how close are we? Annu Rev Med 63:345-57
Gandhi, Kavita; Thera, Mahamadou A; Coulibaly, Drissa et al. (2012) Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg 86:775-81
Thera, Mahamadou A; Doumbo, Ogobara K; Coulibaly, Drissa et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365:1004-13
Lyke, K E; Fernández-Vi?a, M A; Cao, K et al. (2011) Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens 77:562-71

Showing the most recent 10 out of 24 publications